Table 4.

Adverse events considered to be treatment related by investigators (NCI-CTC v4.0).

Adverse events	Number of patients with events (%)
	PD-1 blockade alone (n = 38)		PD-1 blockade-based combination (n = 13)
	Total	Grade 3-4	Total	Grade 3-4
Any	21 (55.3%)	1 (2.6%)	11 (84.6%)	4 (30.8%)
Elevated transaminase	5 (13.2%)	0 (0%)	5 (38.5%)	3 (23.1%)
Elevated bilirubin	1 (2.6%)	0 (0%)	3 (23.1%)	0 (0%)
Anemia	1 (2.6%)	0 (0%)	1 (7.7%)	0 (0%)
Leukopenia	2 (5.3%)	0 (0%)	1 (7.7%)	0 (0%)
Hypothyroidism	4 (10.5%)	0 (0%)	2 (15.4%)	0 (0%)
Hyperthyroidism	2 (5.3%)	0 (0%)	2 (15.4%)	0 (0%)
Elevated myocardial enzyme	1 (2.6%)	0 (0%)	3 (23.1%)	0 (0%)
Elevated creatinine	1 (2.6%)	0 (0%)	1 (7.7%)	0 (0%)
Pyrexia	2 (5.3%)	0 (0%)	4 (30.8%)	0 (0%)
Rash	1 (2.6%)	0 (0%)	1 (7.7%)	0 (0%)
Itchy skin	2 (5.3%)	0 (0%)	1 (7.7%)	0 (0%)
Fatigue	3 (7.9%)	0 (0%)	2 (15.4%)	0 (0%)
Vitiligo	1 (2.6%)	0 (0%)	1 (7.7%)	0 (0%)
Hypertension	1 (2.6%)	1 (2.6%)	4 (40.8%)	0 (0%)
Uveitis	0 (0%)	0 (0%)	1 (7.7%)	1 (7.7%)